In order to serve content on our website, we rely on advertising revenue which helps us to ensure that we continue to serve high quality unbiased journalism.
To know how to disable your Ad Blocker, please
Please refresh your page, once Ad Blocker is disabled
Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.
Pharmalucence, which has sterile injectable capacity in the US, has been acquired by one of the subsidiaries of Sun Pharma, the Mumbai-based firm said in a statement on Wednesday.
The company, however, did not disclose the financial details of the deal.
Earlier this year, Sun Pharma had acquired Ranbaxy Laboratories in an all-stock transaction with a total equity value of USD 3.2 billion along with debt of USD 800 million, taking the overall deal value to USD 4 billion.
Sun Pharma shares were trading at Rs 748.30, up 1.30% from its previous close.